With comments regarding the Capped BTA share price on earlier threads and the inference that the Board or one particular person is talking the share price down.
The revenue BTA are receiving & what one would assume is
going to be ongoing for a lengthy period yet, though sales
of Relenza.
Are the Board not leaving themselves open for a takeover bid by GSK.
Logic would have to dictate that it would possibly be a
cheaper exercise, especially considering the other BTA
products in the pipeline !
- Forums
- ASX - By Stock
- BTA
- what if
what if
-
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)